SCHEMBL6438412

SCHEMBL6438412

Clc1ccc2c(Cl)cnc(Cl)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
NR4A2 P43354 2/20 0.37
POLB P06746 2/20 0.37
KDM4E B2RXH2 1/20 0.37
SOS2 Q07890 1/20 0.37
TP53 P04637 1/20 0.37
AHR P35869 2/20 0.35
PARP1 P09874 2/20 0.35
PLAU P00749 4/20 0.35
GRM4 Q14833 1/20 0.35
CHUK O15111 1/20 0.34
PLG P00747 1/20 0.34
PLAT P00750 1/20 0.34
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28447219 0.91 GRM4 (0.40) ALDH1A1LMNAKMT2AGPR55NR4A2
SCHEMBL31185577 0.79 NT5E (0.39) ALDH1A1LMNAKMT2APOLBKDM4E
SCHEMBL3983900 0.79 NT5E (0.39) ALDH1A1LMNAKMT2APOLBKDM4E
SCHEMBL2617539 0.79 ALDH1A1 (0.40) ALDH1A1LMNAKMT2AGPR55NR4A2
SCHEMBL30133435 0.79 NR4A2 (0.47) ALDH1A1LMNAKMT2AGPR55NR4A2
SCHEMBL23861006 0.79 NR4A2 (0.47) ALDH1A1LMNAKMT2AGPR55NR4A2
SCHEMBL11610310 0.79 POLB (0.43) ALDH1A1LMNAKMT2AGPR55NR4A2
SCHEMBL2617537 0.79 KMT2A (0.36) ALDH1A1LMNAKMT2AGPR55NR4A2
SCHEMBL6433007 0.76 KDM4E (0.33) ALDH1A1POLBKDM4EPLAUGRM4
SCHEMBL15005588 0.75 ALDH1A1 (0.40) ALDH1A1KMT2ANR4A2SOS2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 ALDH1A1 2641/4885LMNA 1451/4885KMT2A 4810/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 ALDH1A1 2641/4885LMNA 1451/4885KMT2A 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.